EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Cell and Gene Therapy: Transforming Treatment Paradigms for Patient‐Centric Care

Sojeong Yi iD, Chia-Yung Wu, Avery McIntosh iD, Maria E Santaella iD, Tara M Robinson, Michael Z Liao iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70430 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Sojeong Yi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Alnylam Pharmaceuticals, Inc, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Patient-Centered Care, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell and gene therapies (CGTs) are transforming medicine by offering potential cures for diseases previously considered untreatable. Despite rapid advancements, challenges remain in optimizing efficacy and safety and ensuring patient accessibility and preference due to high costs and clinical uncertainties, particularly for rare diseases and one‐time administration. The American Society of Clinical Pharmacology & Therapeutics (ASCPT) held a CGT satellite conference in 2025, titled “Cell and Gene Therapy: Transforming Treatment Paradigms for Patient‐Centric Care.” This manuscript summarizes the conference, covering gene therapies and T‐cell immunotherapies from scientific, clinical, and patient‐centered perspectives. Key topics on gene therapy included “platformization” to streamline development, lessons from adeno‐associated virus‐based gene therapies for hemophilia from patient and clinical perspectives, clinical pharmacology, and model‐informed drug development (MIDD) considerations. The conference also highlighted T‐cell immunotherapies including chimeric antigen receptor T therapy (CAR T), focusing on factors affecting cellular kinetics, efficacy, and safety, as well as emerging allogeneic CAR T for autoimmune diseases and MIDD strategies to optimize therapy design and clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyPatient-Centered CareCell- and Tissue-Based TherapyHumansImmunotherapy, AdoptiveT-LymphocytesDependovirusHemophilia A

Stichwörter der Autor:innen

cell‐ and tissue‐based therapygene editinggenetic therapyimmunotherapymodel informed drug development

Autor:innen und Institutionen

  • Alnylam Pharmaceuticals, Inc, Cambridge, Massachusetts, USA.
  • Lima Hui BioConsulting, Seattle, Washington, USA.
  • Pfizer, Inc, Collegeville, Pennsylvania, USA.
  • National Bleeding Disorders Foundation, New York, New York, USA.
  • Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA.
  • Third Arc Bio, Inc, Lower Gwynedd, Pennsylvania, USA.

ORCID-Profile: Sojeong Yi, Avery McIntosh, Maria E Santaella, Michael Z Liao

Zitieren

APA

Yi, S., Wu, C. Y., McIntosh, A., Santaella, M. E., Robinson, T. M., & Liao, M. Z. (2025). Cell and Gene Therapy: Transforming Treatment Paradigms for Patient‐Centric Care. Clinical and Translational Science. https://doi.org/10.1111/cts.70430

Vancouver

Yi S, Wu CY, McIntosh A, Santaella ME, Robinson TM, Liao MZ. Cell and Gene Therapy: Transforming Treatment Paradigms for Patient‐Centric Care. Clinical and Translational Science. 2025. doi:10.1111/cts.70430

BibTeX
@article{Yi2025,
  author = {Yi, Sojeong and Wu, Chia-Yung and McIntosh, Avery and Santaella, Maria E and Robinson, Tara M and Liao, Michael Z},
  title = {Cell and Gene Therapy: Transforming Treatment Paradigms for Patient‐Centric Care},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70430}
}
Kostenlos starten →